Agios Pharmaceuticals

#4833

Rank

$1.93B

Marketcap

United States

Country

Leadership team

Dr. Bruce D. Car DACVP, Ph.D. (Consultant)

Dr. Sarah Gheuens M.D., Ph.D. (Chief Medical Officer and Head of R&D)

Ms. Richa Poddar (Chief Commercial Officer)

Products/ Services

Biotechnology, Health Care, Pharmaceutical

Number of Employees

100 - 500

Headquarters

Cambridge, Massachusetts, United States

Established

2008

Company Registration

SEC CIK number: 0001439222

Revenue

5M - 20M

Traded as

AGIO

Social Media

URL

https://www.agios.com

Overview

Location

Recognition and Award

References

Summary

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

History

Agios Pharmaceuticals was founded in 2007 and made its debut on the NASDAQ in July 2013. Its research and development program has advanced rapidly, and the company soon established itself as a leader in cancer metabolism and inborn errors of metabolism.

Mission

Agios’ mission is to make a transformative impact on patients’ lives through the discovery and development of innovative medicines addressing unmet medical needs.

Vision

Agios' vision is to become a premier, independent biopharmaceutical company focused on oncology and rare genetic metabolic diseases.

Key Team

Dr. Craig B. Thompson M.D. (Co-Founder & Chairman of Scientific Advisory Board)

Mr. Brian M. Goff M.B.A. (CEO & Director)

Ms. Cecilia Jones (Chief Financial Officer)

Dr. Lewis Clayton Cantley Ph.D. (Co-Founder & Member of Scientific Advisory Board)

Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. (Co-Founder & Member of Scientific Advisory Board)

Dr. Shin-San Su Ph.D. (Co-Founder & Member of Scientific Advisory Board)

Mr. T. J. Washburn Jr. (Principal Accounting Officer)

Recognition and Awards

Agios has been the recipient of numerous awards and accolades, including being named the 2016 Scrip Award winner for the ‘Best Emerging Company’ and being named to the Fortune Magazine’s list of “The 100 Fastest-Growing Companies” in 2018.